

# Jurisdiction Specific Medicare Part B Camcevi

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Camcevi	leuprolide mesylate

## Covered Uses

The indications below are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### Prostate Cancer

All other indications will be assessed on an individual basis. Submissions for indications other than those listed in this criteria should be accompanied by supporting evidence from Medicare approved compendia.

## Exclusions

It is contraindicated to administer the requested medication if the member has experienced any type of allergic reaction to the requested medication or to any of its ingredients.

## Coverage Criteria

### Prostate Cancer<sup>1-4</sup>

Authorization of 12 months may be granted for treatment of prostate cancer.

Camcevi MedB Jurisdiction J (AL, GA, TN) and Jurisdiction M (NC, SC, VA, WV) 5743-A P2025.docx © 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Reference number(s)
5743-A

## Dosage and Administration

The dose and frequency of administration must be consistent with the FDA approved labeling. Doses and frequencies that exceed the FDA recommended dosage/frequency as per the prescribing information, are considered not reasonable and necessary.

## References

1. Luteinizing Hormone-Releasing Hormone (LHRH) Analogs LCD (L39387) Version R2. Available at: <https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx>. Accessed February 4, 2025.
2. Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (A59160) Version R4. Available at: <https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx> Accessed February 4, 2025.
3. Camcevi [package insert]. Raleigh, NC: Accord BioPharma Inc.; February 2025.
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 1.2025. [https://www.nccn.org/professionals/physician\\_gls/prostate.pdf](https://www.nccn.org/professionals/physician_gls/prostate.pdf). Accessed February 4, 2025.